about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerPIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapyDetection of circulating tumor DNA in early- and late-stage human malignanciesT-cell receptor gene rearrangement in Epstein-Barr virus infectious mononucleosis.Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal CancerNot all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerationsNovel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancerKRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers.Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience.Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.Epitope recognition in the human-pig comparison model on fixed and embedded material.Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.In situ demonstration of tissue proliferative activity using anti-bromo-deoxyuridine monoclonal antibody.Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study.High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.A case of compound mutations in the MYBPC3 gene associated with biventricular hypertrophy and neonatal death.Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.Intracranial hypotension syndrome: neuroimaging in five spontaneous cases and etiopathogenetic correlations.Proliferating cell nuclear antigen expression in central nervous system neoplasms.Successful management of deep facial burns in a patient with extensive third-degree burns: the role of a nanocrystalline silver dressing in facilitating resurfacing.A quantitative-PCR protocol rapidly detects αGAL deletions/duplications in patients with Anderson-Fabry disease.c.428T > C (p.V143A) homozygous mutation in TP53 gene as a possible mechanism of resistance to trastuzumab therapy in gastric cancer.Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia.ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
P50
Q21142734-6A3FDAFA-1FA5-4B05-A645-C241598BEAA7Q24563539-79F0CC4D-520B-42A6-ABAE-1F7D1CEF47DBQ24604601-C0EE05CC-6656-4C8C-9A6F-28A7220C5089Q27851465-0EA1C677-2BE3-43F7-84CB-B2D4EA722B81Q27853380-C2F8F2AF-2E61-4776-AB31-FA6C9680BA17Q28285473-61962406-536B-461B-9624-41A6276B8CA3Q29615778-4FF462E0-1DE0-47C9-834D-98996C598A01Q33395487-D69F9180-3C11-45F2-9338-F6A17310F8D3Q34501536-C874C0A2-662F-4395-A87D-0076EAB34945Q35029461-ED4755C0-F88A-4389-BEFC-1FACD743F4BBQ36432094-A7DF3696-8F1F-42F4-99D0-7D2D6800D820Q36545375-FABD41D0-867E-4599-9F72-4AB55BA6C93DQ38376337-AF285EC5-F63A-499F-95EF-B18FAF34F296Q38384113-A4C7AF70-128B-4627-AE37-3145043AD13AQ38698206-E46039AF-27B0-4A65-A258-9A410780A43DQ38873794-473613E9-0684-418C-BDAA-19992D1DD7FFQ38880745-73AE1BEE-24E0-49E8-BD98-D65E5CCFC999Q38952923-B5ECF6AC-21BC-43E8-8670-35898622AC5BQ38981486-CF8F308E-733D-4D19-AEB1-AF281A7B986AQ39044610-D0D3556C-B7BF-40B7-A83D-E2D7B88553FAQ39943842-6F37FC45-1D93-43E8-87F3-174D948CD5F4Q40481231-084DCDC8-5445-4FF3-BF5E-17D58BE44F0EQ41548711-EBEB9C3F-1CF0-4773-967A-1F165C06867BQ42183079-4C634F98-6F41-42D2-A192-26F887969972Q42843834-B3DDDFC1-A0EA-43A4-84B4-65C4BB07BE2FQ43211029-FB30C411-0174-413A-A24C-029055DAE3BDQ44524738-FF4765C2-A7AF-4EBF-AA42-D5D4320DB3C2Q44637372-5DB2F337-DF49-4A50-BD8A-3D6FBF012059Q45264394-2124C443-197E-412C-888B-AF109F4A2BEFQ46157168-B7FFA3AE-623B-49C1-AF93-66C1CF4B6A0CQ46465639-7F009064-F42F-4BCE-92C6-340D987C2C8DQ46542092-2EE4EF44-D4D6-441E-9239-8E19E024BDBBQ47949375-84E5AED3-891C-4647-A54C-CE3DDFF51E3BQ48442579-1276B19C-2511-4F56-89EF-86CAD92AE2F0Q48820399-9876C887-D7DD-4B97-AE4C-B46D5A8E3C93Q51027715-E40D12BB-A59A-4322-9C1F-96BA2B5C56CBQ51359587-3B9BD636-F92D-44DB-B508-4580FB71806CQ51540794-52A9E184-411A-4E99-B398-83EAEBDA7189Q53279468-D152F37C-EBF1-492D-A26B-984A32887E87Q53341211-DE295755-A170-4BBB-A17E-FE8A0C06644C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Silvio Marco Veronese
@ast
Silvio Marco Veronese
@en
Silvio Marco Veronese
@es
Silvio Marco Veronese
@nl
Silvio Marco Veronese
@sl
type
label
Silvio Marco Veronese
@ast
Silvio Marco Veronese
@en
Silvio Marco Veronese
@es
Silvio Marco Veronese
@nl
Silvio Marco Veronese
@sl
prefLabel
Silvio Marco Veronese
@ast
Silvio Marco Veronese
@en
Silvio Marco Veronese
@es
Silvio Marco Veronese
@nl
Silvio Marco Veronese
@sl
P106
P1153
6603880933
P21
P31
P496
0000-0002-5280-3740